Halaman 1 dari 25 hasil
FIELD OF THE INVENTION
The present invention relates to new substituted 7,12-dioxabenz[a]anthracene compounds. The compounds of the present invention find advantageous therapeutic use as a result of their antitumor activity.
DESCRIPTION OF THE PRIOR ART
In the literature, the compound
FIELD OF THE INVENTION
This invention relates to a composition and a method useful in treating a number of different types of cancers, and, in particular, carcinomas or melanomas. More particularly, this invention relates to a pharmaceutical composition containing a select class of rhodacyanine dyes
The present invention relates to alkanol derivatives which have been found to be inhibitors of tumor growth. More specifically the invention concerns aminoalkanol derivatives containing an anthracene or substituted anthracene ring system, methods for the synthesis thereof, pharmaceutical
The present invention relates to alkanol derivatives which have been found to be inhibitors of tumor growth. More specifically the invention concerns aminoalkanol derivatives containing an anthracene or substituted anthracene ring system, methods for the synthesis thereof, pharmaceutical
BRIEF SUMMARY OF THE INVENTION
This invention relates to new organic compounds and, more particularly, is concerned with novel substituted 9,10-bis(2-aminoethoxy)anthracenes which may be represented by the following general formula: ##STR1## wherein R.sub.1 and R.sub.2 are each individually selected
BACKGROUND OF THE INVENTION
1. Field Of The Invention
This invention relates to novel anthracene compounds useful in the treatment of allergic, inflammatory, and tumor conditions, and to therapeutic compositions containing such compounds. The invention provides therapeutic compositions effective at
BACKGROUND OF INVENTION
(a) Field of the Invention
This invention relates to unsymmetrical 1,4-bis-(aminoalkylamino)-anthracene-9,10-diones and derivatives thereof. The invention also relates to a process of preparing these compounds as well as to the treatment of human neoplasms in an animal
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention relates to novel metal chelates of anthracene-9,10-bis-carbonylhydrazones and their acid-addition and quaternary ammonium salts, to the use of such compounds as antibacterial agents, for inhibiting the growth of transplanted
The invention concerns specific anthracene compounds for therapeutic applications, and also pharmaceuticals containing these compounds.
Karwinskia humboldtiana is a bush of the rhamnaceae family which is common in the semi-deserts of North and Central America and in the southwestern U.S.A. and is
FIELD OF THE INVENTION
The present invention relates to novel prodrugs of biologically active anthracene-9, 10-dione dioxime compounds, their intermediates, methods for synthesizing, and their use to treat cancer and other diseases.
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention relates to novel prodrugs of biologically active anthracene-9, 10-dione dioxime compounds, their intermediates, methods for synthesizing, and their use to treat cancer and other diseases.
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of
FIELD OF THE INVENTION
The present invention relates to the field of novel compounds useful for the treatment of cancer and methods of use thereof.
BACKGROUND OF THE INVENTION
The Wnt/beta-catenin signaling pathway is recognized as one of the key signaling pathways in cancer and as a valid target
FIELD OF THE INVENTION
The present invention relates to the field of novel compounds useful for the treatment of cancer and methods of use thereof.
BACKGROUND OF THE INVENTION
The Wnt/beta-catenin signaling pathway is recognized as one of the key signaling pathways in cancer and as a valid target
FIELD OF THE INVENTION
The present invention relates to the field of novel compounds useful for the treatment of cancer and methods of use thereof.
BACKGROUND OF THE INVENTION
The Wnt/beta-catenin signaling pathway is recognized as one of the key signaling pathways in cancer and as a valid target
FIELD OF THE INVENTION
The present invention relates to an improved liposome/anthraquinone therapeutic composition having reduced lipid oxidation and free-radical damage, and to methods for preparing and using the composition.
REFERENCES
Aubel-Sadron, G., et al, Biochemie, 66:333 (1984).
Augustin,